BAM
IMCR icon

Blueshift Asset Management’s Immunocore IMCR Stock Holding History

Blueshift Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,195
Closed -$257K – 534
2025
Q2 		$257K Buy
+8,195
New +$255K 0.08% 323

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blueshift Asset Management's IMCR Position: Q3 2025 in Review

Blueshift Asset Management sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 8,195 shares — an estimated $257K sold.

Blueshift Asset Management first reported a position in IMCR in Q2 2025 and held it in 1 quarter. The position peaked at $257K in Q2 2025. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

  • Blueshift Asset Management reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
  • Blueshift Asset Management sold 8,195 Immunocore shares in Q3 2025, an estimated $257K.
  • Blueshift Asset Management first reported a position in Immunocore in Q2 2025 and held it in 1 quarter.
  • Blueshift Asset Management's Immunocore position peaked at $257K in Q2 2025.
  • 132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on Blueshift Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.